Blume-Jensen Peter 4
4 · Acrivon Therapeutics, Inc. · Filed Jan 16, 2026
Insider Transaction Report
Form 4
Blume-Jensen Peter
DirectorPresident and CEO
Transactions
- Purchase
Common Stock
[F1][F2]2026-01-14$1.68/sh+49,000$82,124→ 2,095,771 total
Holdings
- 314,706(indirect: See Footnote)
Common Stock
[F3]
Footnotes (3)
- [F1]The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.66 to $1.68, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.
- [F2]These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- [F3]These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.